Exploring the influence of inhaled liposome membrane fluidity on its interaction with pulmonary physiological barriers
Source abstract
Abstract
Liposomes are promising vectors for pulmonary drug delivery, and have been used in marketed inhalation products. Membrane fluidity is an important property of liposomes. However, the influence of liposome membrane fluidity on its interaction with pulmonary physiological barriers is still unclear and needs elucidation. Here, a series of PEGylated DPPC (1,2-dihexadecanoyl-rac-glycero-3-phosphocholine) liposomes with different membrane fluidity were prepared, and their interaction with different pulmonary physiological barriers, including the mucus permeation capacity, macrophage uptake, trachea distribution and retention behavior, was investigated. The liposomes exhibited sizes of around 100 nm, near-neutral surface charge, and the membrane fluidity increased with increasing cholesterol ratio. In vitro studies showed that the liposomes with lower membrane fluidity presented optimal mucus permeation efficiency, while those with higher membrane fluidity displayed lower macrophage uptake. An in vivo trachea distribution study revealed that liposomes with low or medium membrane fluidity exhibited enhanced trachea permeation. No significant difference in lung retention was found among these liposomes. In conclusion, the mucus permeation and macrophage phagocytosis behavior of liposomes could be well tuned by changing their membrane fluidity.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy
Shenyang Pharmaceutical University
Shenyang 110016
China
Funding
National Key Research and Development Program of China
References (45)
Show source-provided references
1. K. P. O'Donnell and H. D. C.Smyth , in Controlled Pulmonary Drug Delivery , ed. H. D. C. Smyth and A. J. Hickey , Springer , New York , 2011 , ch. 1, pp. 1–4
2. I. M. El-Sherbiny , D. G.Villanueva , D.Herrera and H. D. C.Smyth , in Controlled Pulmonary Drug Delivery , ed. H. D. C. Smyth and A. J. Hickey , Springer , New York , 2011 , ch. 5, pp. 102–103
3. Liu · Drug Discovery Today · 2020 · 25 · 15010.1016/j.drudis.2019.09.023 ↗
4. Wong · J. Controlled Release · 2003 · 92 · 26510.1016/S0168-3659(03)00358-4 ↗
5. Nahar · Pharm. Res. · 2016 · 33 · 169610.1007/s11095-016-1911-7 ↗
6. Takechi-Haraya · Langmuir · 2016 · 32 · 607410.1021/acs.langmuir.6b00741 ↗
7. Jovanović · Eur. J. Lipid Sci. Technol. · 2018 · 120 · 180003910.1002/ejlt.201800039 ↗
8. Hanashima · Chirality · 2020 · 32 · 28210.1002/chir.23171 ↗
9. Yano · Biophys. J. · 2018 · 115 · 153010.1016/j.bpj.2018.08.042 ↗
10. Liang · J. Colloid Interface Sci. · 2004 · 278 · 5310.1016/j.jcis.2004.05.042 ↗
11. Takechi-Haraya · AAPS PharmSciTech · 2017 · 18 · 188710.1208/s12249-016-0624-x ↗
12. Bellavance · Int. J. Pharm. · 2010 · 395 · 25110.1016/j.ijpharm.2010.05.017 ↗
13. Kawano · Mol. Pharm. · 2009 · 6 · 9810.1021/mp800069c ↗
14. Orthmann · J. Pharm. Sci. · 2010 · 99 · 242310.1002/jps.22001 ↗
15. Yu · Proc. Natl. Acad. Sci. U. S. A. · 2019 · 116 · 536210.1073/pnas.1818924116 ↗
16. Franzé · Mol. Pharm. · 2017 · 14 · 199810.1021/acs.molpharmaceut.7b00099 ↗
17. Wu · Acta Pharm. Sin. B · 2019 · 9 · 85810.1016/j.apsb.2019.02.010 ↗
18. Takechi-Haraya · Mol. Pharm. · 2017 · 14 · 215810.1021/acs.molpharmaceut.7b00051 ↗
19. Lopez-Rodriguez · Biochim. Biophys. Acta, Biomembr. · 2014 · 1838 · 156810.1016/j.bbamem.2014.01.028 ↗
20. Dong · Int. J. Pharm. · 2018 · 547 · 49910.1016/j.ijpharm.2018.05.076 ↗
21. Conte · J. Controlled Release · 2018 · 277 · 12610.1016/j.jconrel.2018.03.011 ↗
22. Angelo · Colloids Surf., B · 2015 · 135 · 71710.1016/j.colsurfb.2015.08.027 ↗
23. Pellosi · Eur. J. Pharm. Biopharm. · 2018 · 130 · 3010.1016/j.ejpb.2018.06.006 ↗
24. Li · Eur. J. Pharm. Biopharm. · 2019 · 143 · 7010.1016/j.ejpb.2019.08.017 ↗
25. Kaur · Mol. Pharm. · 2014 · 11 · 19710.1021/mp400372j ↗
26. Sreekanth · J. Phys. Chem. B · 2013 · 117 · 1213510.1021/jp406340y ↗
27. Suga · Langmuir · 2013 · 29 · 483010.1021/la304768f ↗
28. Parasassi · J. Fluoresc. · 1998 · 8 · 36510.1023/A:1020528716621 ↗
29. Bhattacharya · J. Phys. Chem. B · 2007 · 111 · 246310.1021/jp068383w ↗
30. Coderch · J. Controlled Release · 2000 · 68 · 8510.1016/S0168-3659(00)00240-6 ↗
31. Silva · J. Colloid Interface Sci. · 2011 · 358 · 19210.1016/j.jcis.2011.02.048 ↗
32. Epand · Chem. Phys. Lipids · 2003 · 122 · 3310.1016/S0009-3084(02)00176-7 ↗
33. Bui · Langmuir · 2019 · 35 · 1064010.1021/acs.langmuir.9b01538 ↗
34. Florence · J. Controlled Release · 2012 · 164 · 11510.1016/j.jconrel.2012.03.022 ↗
35. Tian · Acta Mech. Sin. · 2019 · 35 · 37610.1007/s10409-019-00858-x ↗
36. Yu · Nat. Commun. · 2018 · 9 · 260710.1038/s41467-018-05061-3 ↗
37. Yang · Nat. Nanotechnol. · 2010 · 5 · 57910.1038/nnano.2010.141 ↗
38. Patel · Eur. J. Pharm. Biopharm. · 2015 · 89 · 16310.1016/j.ejpb.2014.12.001 ↗
39. Banquy · Soft Matter · 2009 · 5 · 398410.1039/b821583a ↗
40. Palomba · ACS Nano · 2018 · 12 · 143310.1021/acsnano.7b07797 ↗
41. Yi · Phys. Rev. Lett. · 2011 · 107 · 09810110.1103/PhysRevLett.107.098101 ↗
42. Sun · Adv. Mater. · 2015 · 27 · 140210.1002/adma.201404788 ↗
43. Lai · Adv. Drug Delivery Rev. · 2009 · 61 · 15810.1016/j.addr.2008.11.002 ↗
44. Stern · J. Controlled Release · 2017 · 257 · 4010.1016/j.jconrel.2016.12.013 ↗
45. Garcia-Mouton · Eur. J. Pharm. Biopharm. · 2019 · 144 · 23010.1016/j.ejpb.2019.09.020 ↗